PDGFR
PDGFR (platelet-derived growth factor receptor) is a group of cell surface tyrosine kinase receptors for members of the PDGF (platelet-derived growth factor) family.
Products Related to PDGFR(111)
- GC69619OlaratumabCAS: 1024603-93-7Purity: >95.00%
Olaratumab (IMC-3G3; LY3012207) is a human monoclonal IgG1 antibody against platelet-derived growth factor receptor alpha (PDGFRα), which has anti-tumor activity.
- GC70992AnsornitinibCAS: 1448874-96-1Purity: >98.00%
Ansornitinib ist ein oral aktiver Dual-Kinase-Inhibitor, der den Thrombozyten-derived growth factor receptor (PDGFR) und den vaskulären endothelialen growth factor receptor (VEGFR2) hemmt.
- GC72911Pazopanib-13C,d3 hydrochlorideCAS: 1261398-44-0Purity: >97.00%
Pazopanib-13C,d3 hydrochloride ist das Deuterium- und 13C-markierte Pazopanib-Drochlorid.
- GC81305Tyrosine kinase-IN-11CAS: 3031972-21-8Purity: >98.50%
Tyrosine kinase-IN-11 (Compound 4b) is a tyrosine kinase inhibitor.
- GC81321Pegpleranib sodiumPurity: >98.00%
Pegpleranib (Fovista) sodium is a pegylated DNA aptamer that selectively binds to PDGF-BB and PDGF-AB homodimers and heterodimers, interrupting the interaction with their associated tyrosine kinase receptors.
- GC81323PDGFRA/CAIX/XII-IN-1Purity: >98.00%
PDGFRA/CAIX/XII-IN-1 is an inhibitor of PDGFRA, CA IX and CA XII, with an IC 50 of 20 nM against PDGFRA, a K i of 93.3 nM against CA IX, and a K i of 80.0 nM against CA XII.
- GC81325VEGFR2-IN-84CAS: 861877-12-5Purity: >98%
VEGFR2-IN-84 is an orally active, multi-targeted tyrosine kinase inhibitor based on a naphthalene ring scaffold.
- GC17651SunitinibCAS: 557795-19-4Purity: >98.00%
Sunitinib (SU 11248) ist ein Multi-Targeting-Rezeptor-Tyrosinkinase-Inhibitor mit IC50-Werten von 80 nM bzw. 2 nM fÜr VEGFR2 und PDGFRβ. Sunitinib, ein ATP-kompetitiver Inhibitor, hemmt wirksam die Autophosphorylierung von Ire1α, indem es die Autophosphorylierung und die daraus resultierende RNase-Aktivierung hemmt.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC66385 | Tovetumab | 1243266-04-7 | >99.00% | |
Tovetumab (MEDI-575) ist ein Anti-PDGFRα monoklonaler AntikÖrper, der selektiv PDGFRα blockiert; Signaltransduktion. Tovetumab kann bei der Erforschung von Glioblastom und nicht-kleinzelligem Lungenkrebs (NSCLC) eingesetzt werden. | ||||
| GC67774 | CT52923 | 205256-55-9 | >98.00% | |
| GC69619 | Olaratumab | 1024603-93-7 | >95.00% | |
Olaratumab (IMC-3G3; LY3012207) is a human monoclonal IgG1 antibody against platelet-derived growth factor receptor alpha (PDGFRα), which has anti-tumor activity. | ||||
| GC70992 | Ansornitinib | 1448874-96-1 | >98.00% | |
Ansornitinib ist ein oral aktiver Dual-Kinase-Inhibitor, der den Thrombozyten-derived growth factor receptor (PDGFR) und den vaskulären endothelialen growth factor receptor (VEGFR2) hemmt. | ||||
| GC72911 | Pazopanib-13C,d3 hydrochloride | 1261398-44-0 | >97.00% | |
Pazopanib-13C,d3 hydrochloride ist das Deuterium- und 13C-markierte Pazopanib-Drochlorid. | ||||
| GC73370 | AXL-IN-13 | 2376928-82-2 | >98.00% | |
AXL-IN-13 ist ein potenter und oral aktiver AXL-Inhibitor (IC50: 1.6 nM, Kd: 0.26 nM). | ||||
| GC81304 | GW296115 | 118458-58-5 | >98.50% | |
GW296115 is a multi-target inhibitor with the following IC 50 values against its targets: 8.4 nM for BRSK2, 21 nM for BRSK1, 1.8 μM for PDGFRβ, 5.5 nM for STK17B/DRAK2, 28 nM for DRAK1, 20 nM for PHKG1, and 89 nM for DCAMKL3. | ||||
| GC81305 | Tyrosine kinase-IN-11 | 3031972-21-8 | >98.50% | |
Tyrosine kinase-IN-11 (Compound 4b) is a tyrosine kinase inhibitor. | ||||
| GC81321 | Pegpleranib sodium | - | >98.00% | |
Pegpleranib (Fovista) sodium is a pegylated DNA aptamer that selectively binds to PDGF-BB and PDGF-AB homodimers and heterodimers, interrupting the interaction with their associated tyrosine kinase receptors. | ||||
| GC81323 | PDGFRA/CAIX/XII-IN-1 | - | >98.00% | |
PDGFRA/CAIX/XII-IN-1 is an inhibitor of PDGFRA, CA IX and CA XII, with an IC 50 of 20 nM against PDGFRA, a K i of 93.3 nM against CA IX, and a K i of 80.0 nM against CA XII. | ||||
| GC81325 | VEGFR2-IN-84 | 861877-12-5 | >98% | |
VEGFR2-IN-84 is an orally active, multi-targeted tyrosine kinase inhibitor based on a naphthalene ring scaffold. | ||||
| GC81443 | E8431 | 2419580-01-9 | >97.00% | |
E8431 is a DCSTAMP antagonist with an IC 50 value of 775.8 nM for osteoclastogenesis. | ||||
| GC91419 | CYY292 | 2644673-04-9 | >98.00% | |
CYY292 ist ein Inhibitor von PDGFRα, PDGFRβ, FGFR1,-2 und -3 (IC50s = 5,35, 4,6, 28, 28 bzw. 78 nM). | ||||
| GN10603 | Sennoside B | 128-57-4 | >99.00% | |
| GC17651 | Sunitinib | 557795-19-4 | >98.00% | |
Sunitinib (SU 11248) ist ein Multi-Targeting-Rezeptor-Tyrosinkinase-Inhibitor mit IC50-Werten von 80 nM bzw. 2 nM fÜr VEGFR2 und PDGFRβ. Sunitinib, ein ATP-kompetitiver Inhibitor, hemmt wirksam die Autophosphorylierung von Ire1α, indem es die Autophosphorylierung und die daraus resultierende RNase-Aktivierung hemmt. | ||||
